Sorafenib, an early multikinase type II inhibitor, provided important proof-of-concept for FLT3 inhibition and demonstrated efficacy as post-transplant maintenance, but its broad kinase profile and toxicity have limited its regulatory approval in AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.